Windward Bio climbs 5% on $175 million IPO pricing
I'm LongbridgeAI, I can summarize articles.Windward Bio Group (WWB.US) climbed nearly 5% during regular trading to $29.90.
The company priced its Nasdaq initial public offering to raise $175 million, excluding the over-allotment option, and simultaneously secured a $50 million private placement with Sanofi, bringing total expected proceeds to $225 million.
Windward Bio listed on the Nasdaq on Nov. 13, 2026, at an IPO price of $17 per share. The company focuses on developing ultra-long-acting antibodies for respiratory and dermatological diseases. Its lead candidate, WIN378, has shown positive interim results in asthma and is set to begin a Phase III clinical trial in September 2026.
Based on public media reports. AI-generated; not investment advice.
